Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL530525 | 0.93 | LMNA (0.41) | LMNATSHRCHRM2CHRM4CHRM5 | |
| Benzene SCHEMBL8861746 | 0.75 | TSHR (0.46) | LMNATSHRCHRM2CHRM4CHRM5 | |
| SCHEMBL530220 | 0.75 | TSHR (0.33) | TSHR | |
| SCHEMBL6724769 | 0.72 | TSHR (0.35) | TSHR | |
| SCHEMBL530219 | 0.72 | TSHR (0.35) | TSHR | |
| SCHEMBL6724775 | 0.71 | TSHR (0.31) | TSHR | |
| SCHEMBL22325533 | 0.70 | TSHR (0.52) | TSHRCHRM2CHRM4CHRM1MAPT | |
| SCHEMBL4186678 | 0.70 | — | — | |
| SCHEMBL467571 | 0.70 | LMNA (0.39) | LMNATSHRCHRM2CHRM4CHRM5 | |
| SCHEMBL26980836 | 0.70 | CHRM2 (0.30) | LMNATSHRCHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166666-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2024-05-23 | — | — | US | disclosed |
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2024-04-25 | — | — | US | disclosed |
| EP-4025253-B1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR SA (ES) | 2024-03-20 | — | — | EP | disclosed |
| EP-3615544-B9 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2024-01-03 | — | — | EP | disclosed |
| EP-4101855-B9 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2024-01-03 | — | — | EP | disclosed |
| EP-4101855-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2023-08-02 | — | — | EP | disclosed |
| US-11713325-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2023-08-01 | — | — | US | disclosed |
| US-20230218774-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2023-07-13 | — | — | US | disclosed |
| WO-2023067132-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2023-04-27 | — | — | WO | disclosed |
| EP-3615544-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2023-03-22 | — | — | EP | disclosed |
| WO-2018050795-A1 | PROCESS FOR PREPARING OF CAROTENOID MONO-ESTERS | BASF SE (DE) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018050793-A1 | PROCESS FOR PREPARING PHOSPHONIUM SALT ESTERS AS BUILDING BLOCKS FOR CAROTENOIDES | BASF SE (DE) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018050792-A1 | PROCESS FOR PREPARING ESTERS OF 12'-APOCAROTENALS AS BUILDING BLOCKS FOR CAROTENOIDS | BASF SE (DE) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018050794-A1 | PROCESS FOR PREPARING OF CAROTENOID MONO-ESTERS | BASF SE (DE) | 2018-03-22 | — | — | WO | disclosed |
| US-20160207932-A1 | NOVEL TRICYCLIC CHIRAL COMPOUNDS AND THEIR USE IN ASYMMETRIC CATALYSIS | UNIV NANYANG TECH (SG) | 2016-07-21 | — | — | US | disclosed |
| US-9206090-B2 | Tricyclic chiral compounds and their use in asymmetric catalysis | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2015-12-08 | — | — | US | disclosed |
| CN-101932592-B | Antitumoral compounds | PHARMA MAR SA | 2014-02-26 | — | — | CN | disclosed |
| US-20110269972-A1 | NOVEL TRICYCLIC CHIRAL COMPOUNDS AND THEIR USE IN ASYMMETRIC CATALYSIS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2011-11-03 | — | — | US | disclosed |
| CN-101932592-A | Antineoplastic compound | PHARMA MAR SA | 2010-12-29 | — | — | CN | disclosed |
| WO-2010027334-A1 | NOVEL TRICYCLIC CHIRAL COMPOUNDS AND THEIR USE IN ASYMMETRIC CATALYSIS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269972-A1 | NOVEL TRICYCLIC CHIRAL COMPOUNDS AND THEIR USE IN ASYMMETRIC CATALYSIS | SCO2, CBR3, HCCS | LMNA 4107/4885TSHR 839/4885CHRM2 191/4885 |
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | STT3B, STT3A, TTL | LMNA 1254/4885TSHR 1530/4885CHRM2 4323/4885 |
| US-20160207932-A1 | NOVEL TRICYCLIC CHIRAL COMPOUNDS AND THEIR USE IN ASYMMETRIC CATALYSIS | COX6C, CBR3, CYCS | LMNA 2287/4885TSHR 1377/4885CHRM2 56/4885 |
| US-20240166666-A1 | ANTITUMORAL COMPOUNDS | TP53, TOP1, MCL1 | LMNA 1898/4885TSHR 4670/4885CHRM2 4849/4885 |
| US-11713325-B2 | Antitumoral compounds | TP53, TOP1, MCL1 | LMNA 1898/4885TSHR 4670/4885CHRM2 4849/4885 |
| US-20230218774-A1 | DRUG ANTIBODY CONJUGATES | B3GAT3, MGAT3, SDAD1 | LMNA 3861/4885TSHR 1572/4885CHRM2 4501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.